Return to content in this issue


A reply letter to ´Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis´

Lihang L, Han Y

Department of Dermatology, the Union Hospital, Fujian Medical University, Fuzhou, P.R. China

J Investig Allergol Clin Immunol 2022; Vol. 32(4)
doi: 10.18176/jiaci.0745

Key words: Nemolizumab, Atopic Dermatitis